• DNA replication timing of >100 pediatric leukemic samples identified BCP-ALL subtype-specific genome alteration signatures.
INTRODUCTION
DNA replication timing (RT) refers to the temporal order in which defined units of chromosomes replicate during the course of S phase. The regulatory units of RT correspond to units of structural organization and are organized into higher-order 3D spatial compartments in the nucleus that replicate at distinct times during S phase 1, 2 . Changes in RT affect at least half of the genome during normal development and differentiation 1, 3, 4 and RT profiles are characteristic of a given cell type [5] [6] [7] [8] . Early RT correlates with transcriptional activity, but there are many exceptions 9, 10 and "RT signatures" can identify differences between diseased and normal tissue that are not identified by standard transcriptome analyses 11, 12 . RT signatures may therefore provide a novel genre of clinical biomarkers reflective of large-scale genome architecture. We previously described disease-and patient-specific features in the RT profiles of Blineage precursor acute lymphoid leukemia (BCP-ALL) cells 2, 13 and showed these remained stable in serially passed patient-derived xenografts (PDX) in immunodeficient mice 14 . Here, we investigated the biological relevance of RT alterations to BCP-ALL by examining the relationship of BCP-ALL RT profiles to specific stages of normal B-cell differentiation from which this class of leukemias derive, and their potential prognostic significance. Results establish the existence of leukemia-specific RT signatures that include previously unknown associations with specific BCP-ALL subtypes and their responses to therapy. 
METHODS

RESULTS
RT signatures of normal human hematopoietic cell types
We transplanted normal human CD34+ CB cells into sub-lethally irradiated Non-obese diabetic-Rag1 -/-IL2Rγc -/-(NRG) mice and isolated human CD34+CD38-, CD34+CD19+, CD34-CD19+ and total CD34+ (mixed progenitors) cells by fluorescent activated cell sorting (FACS) from their bone marrow and spleens 2-3 months later (Figure 1A) . Biological replicates consisted of cells regenerated from different pooled sources of CB cells. The CD34+CD19+ and CD34-CD19+ cells obtained in one of the replicate experiments were also sorted for the presence or absence of ROR1 expression. As expected 21 , CD34+CD19+ROR1+ cells were rare allowing purification of only 300 cells from the early and late Sphase fractions, simultaneously sorted for surface marker expression and DNA content, from which good quality Repli-seq profiles were then also obtained.
RT profiles were generated by Repli-chip 16 or Repli-seq 17 as described in the Methods and illustrated in Figure 1B and 1C. RT signatures specific to differentiating B-cells were derived by comparisons with similarly generated RT profiles obtained for other normal human hematopoietic cells, including our previously reported data for granulopoietic and erythroid cells generated from adult mobilized peripheral blood cells, stimulated adult T-cells, and a series of Epstein Barr virus (EBV)-immortalized B-cell lines 7 with a stringent quality control cut-off 16, 17 .
We then derived RT "signatures" using a pipeline that identifies regions of the genome that replicate at times unique to each of 26 normal human cell types 7 . In brief, after removing reads from the sex chromosomes, remaining mappable reads for each cell type were first divided into 55,940 50-kb segments each of which was then assigned an RT value (Supplemental Figure S1A) . We then applied an unsupervised K-means clustering analysis to all 50-kb genomic segments that changed their RT from a log2 ratio ≥0.5 to ≤-0.5 (or vice versa) 7 to identify 10,350 features (18.5% of the genome) that replicate significantly differently between cell types (p-value <2x10 -16 using T-tests). Correlation matrix (Supple- (Figure 1D-F) . Moreover, multiple known key regulators of hematopoiesis were found in each signature; for example, HMGA2, KIT and HOX genes that are required for self-renewal activity in hematopoietic stem cells 23, 24 ;
CREB5 linked to quiescence of early precursors; RUNX2 required for HSC differentiation 25 ; and CD79B is required for the pro-B/pre-B transition 26 (Figure 1D-F and Supplemental Table S2 ). Together, these results indicate that RT features can discriminate phenotypically different hematopoietic cell types.
BCP-ALL-specific RT signatures
Genome-wide RT profiles generated on a panel of 97 BCP-ALL patient samples and cell lines, and more limited numbers of pediatric AML and T-ALL patient samples and cell lines ( Supplemental Table S1 ).
Although our standard E/L method (Figure 2A ) performs well on samples of freshly obtained leukemic cells from patients 13 or transplanted mice 14 , the numbers of viable cells or cells able to incorporate BrdU that we obtained from many frozen banked samples were very low, consistent with S-phase specific replication fork collapse 27 . For these we first sorted unlabeled S-phase and G1 phase cells by FACS based on their DNA content (Figure 2A) . We then used microarray or whole genome sequencing (WGS) to obtain the relative copy numbers of each 50-kb sequence in S and G1 and derived RT profiles from the fact that earlier replicating sequences are higher in copy number than late replicating sequences in S phase, but are at equal copy number in G1 phase (Figure 2A ; S/G1 Repli-seq) 14, 28 . Since the dynamic range of G1/S data is inherently <2-fold, a large number of sequencing reads is needed to quantify copy numbers (160 million per sample), making it expensive as a routine assay. Thus, we designed a set of capture oligonucleotides spaced evenly throughout the genome (see Materials and Methods) that significantly reduced the sequence depth required to cover the breadth of the genome (10 7 mappable reads) and also enabled high resolution RT profiles to be obtained, scaled and normalized with all other samples ( Figure 2B ). Clustering demonstrated a high concordance between replicate datasets and confirmed a lack of bias from the different methods used (Figure 2C) .
Comparison of the RT programs from the leukemia patient samples and cell lines with one another using the same pipeline revealed 3,540 50-kb variable segments (6.3% of the autosomal genome) that showed significant differences and generated 14 RT signatures ( Figure 3A) . Six of these were linked to patients and cell lines containing the t(1;19) translocation that encodes the TCF3-PBX1 fusion protein (#1 to #6 in Figure 3A and 3B). TCF3 (also known as E2A) is a transcription factor required for normal B-(and T-) cell differentiation and has been implicated in many lymphoid malignancies 29, 30 . PBX1 is a proto-oncogene with a critical role in hematopoiesis and lymphopoiesis 31 . The TCF3-PBX1 fusion gene is believed to be a driver mutation in the BCP-ALLs in which it is found 32 . The #1 and #2 RT signatures were early replicating and #6 was late replicating uniquely in the TCF3-PBX1-positive samples. The fact that all 3 TCF3-PBX1-positive cell lines shared the same RT signatures as the patients' TCF3-PBX1positive leukemic cells underscores the epigenetic stability of their identified RT signatures. Interestingly, signatures #3, #4 and #5 sub-stratified the TCF3-PBX1 samples, with signatures #3 and #5 found to be shared with an established cell line from an AML patient (MOLM1), but not with any of the two other AML patients' samples. In addition, most of the regions in RT signature #1 that were early replicating uniquely in the TCF3-PBX1-positive patients' cells were also very late in both T-ALL and AML cells.
Commonalities between T-ALL and AML cells may not be driven by known similarities between AML
and Early T-cell precursor T-ALL (ETP ALL) 33 , since T-ALL sample 10-799 is not categorized as ETP ALL ( Supplemental Table S1 ) and RT signatures #3 and #5, which were common to the AML and some TCF3-PBX1-positive samples, also distinguished AML from T-ALL. RT signature #8 was early replicating in a group of BCP-ALL samples of unknown genotype, and #9 was shared between these and certain AML samples. RT signatures #10, #11, and #12 identified known subsets of BCP-ALL samples. Signature #13 was late in one case and #14 was late in 2 others. The exclusivity of these RT Figure 3D) , which also did not contain a TCF3-TFPT fusion gene ( Supplemental Table S1 ) 34 . Next, we analyzed the gene expression patterns within these RT signatures using transcriptome data from 508 B-ALL samples generated by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) from patients enrolled in Children's Oncology Group (COG) clinical trials 35 . This analysis identified genes with coordinated changes in transcriptional activity and RT ( Figure 3C and Supplemental Figure S3 ). Among the genes overexpressed in RT signature #1 we identified WNT16, GLT1D1, ROR1 and others ( Figure 3D ).
WNT16 has been shown to be a target of the TCF3-PBX fusion protein and is associated with the leukemogenesis of this BCP-ALL subtype 36 . GLT1D is also upregulated in TCF3-PBX1-positive cells but not in patients with TCF3-HLF translocation 37 . ROR1 encodes for the receptor orphan tyrosine kinase receptor 1 and it enhances the viability of TCF3-PBX1-positive cells 38, 39 . Supplemental Table S3 contains the complete gene list for all B-ALL RT signatures shown in Figure 3C . 
RT signatures associated with CNS relapse in TCF3-PBX1-positive BCP-ALL patients
Although most TCF3-PBX1-positive BCP-ALL patients are cured with current therapies, ~10% currently relapse with a high incidence of central nervous system (CNS) relapse [41] [42] [43] . We analyzed WGS data (28X coverage) derived from 21 TCF3-PBX1-positive BCP-ALL patients at diagnosis by the St. Jude's Pediatric Cancer Genome Project (PCGP). First, we identified differences in copy number variation (CNV) and detected multiple amplified loci in all TCF3-PBX1-positive patients but we did not detected differences that distinguished patients with CNS relapse (Supplemental Figure S4 ). Next we exploited the deep coverage of this WGS data to generate RT profiles based on the fact that earlier replicating sequences are higher in copy number than late replicating sequences ( Figure 5A RT signature #1 contained features that were early replicating in the cells from the CNS relapse samples but late in all other TCF3-PBX1-positive BCP-ALL patients. Gene ontology (GO) analysis of these chromosomal segments indicated that genes within this signature are associated with neurological regulation ( Figure 5E) ; specifically, this ontology term is linked to genes from the opiorphin family (SMR3A, SMR3B
and OPRPN) which are up-regulated in head and neck squamous cell carcinoma (HNSCC) 44 . Additionally, odontogenesis regulation was also associated with this RT signature, derived from genes AMBN, AMTN, ODAM, ENAM, which are evolutionarily related genes all located within 500 kb of each other on chromosome 4 45 . RT signature #2 contained features that were later replicating in samples from patients that developed CNS relapse but early in samples derived from patients in remission. GO analysis indicated that genes within this signature were associated with glial cell fate determination (Gene CTNNB1), neural plate development (Gene CTNNB1), establishment of endothelial blood-brain barrier (Gene CTNNB1) and regulation of neuron migration (Gene ULK4) (Figure 5E ). CTNNB1 and ULK4 are located within 500 kb of each other on chromosome 3 (Figure 5D ). CTNNB1 encodes for β-catenin, is among the most frequently mutated genes in human cancer 46 and has the highest mutation frequency within RT signatures #1 and #2 ( Figure 5F) . Importantly, other genes reside in the domains with these GOterm driving genes, so further investigation is required to confirm any link between these genes and cellular phenotypes. Supplemental Table S4 contains the complete gene list for these RT signatures.
RT signatures associated with relapse in NOS BCP-ALL patients
A total of 120 NOS samples were obtained from the COG bank. 60 of these were from patients classified as high risk; 30 from patients that relapsed within 3 years and 30 from patients who were still in remission after at least 3 years. Because most of these samples had too few cells to support the generation of high-quality RT profiles, we selected the 5 highest quality datasets each from paired set of relapse and remission samples and generated RT signatures ( Figure 6A ). This analysis revealed 4 RT relapsespecific signatures, one of which was found in all relapses, one in 3 relapse samples and 2 in 2 relapse samples ( Figure 6B ). For all 4 signatures, all remission samples were identical. Thus, despite the high degree of heterogeneity of NOS samples, their relapse RT signatures showed several associated features. Genes found within these RT signatures are listed in Supplemental Table S5 . GO analysis identified genes associated with interleukin-5 signaling and B-cell activation for RT signature #1; and leukocyte tethering, interleukin-35 and interleukin-21 signaling for RT signature #3 (Figure 6C ). GO terms derived from genes IL5RA and ITPR1, which are required for B-cell development and have the highest mutation frequency within the NOS-RT signatures (Figure 6D ).
Matching leukemia-specific RT signatures to RT profiles of normal human hematopoietic cell types
To identify features of the leukemic cell RT signatures that might match those of normal hematopoietic cells and or subsets of these at different stages of differentiation, we performed a hierarchical clustering analysis of the RT data for the subsets of genomic segments from the RT signature #1 that distinguish the TCF3-PBX1-positive samples including the normal blood cell types ( Figure 3A) . The genomic regions from this RT signature display heterogenous patterns of RT in mature B-cells and T-cells ( Figure   7A ). Thus, we identified sub-signatures by further dividing this subset of genomic regions by k-means clustering analysis (Figure 7B ). This analysis identified three groups of features within signature #1, one shared with normal pre-B cells (late B-precursors) but not normal pro-B or mature B cell lines (1A in Figure 7AB ), a second set shared with mature B-cell lines but not normal pre-or pro-B cells (1B in Figure 7AB ), and a third set not shared with any of the nonleukemic B-cells analyzed (1C in Figure   7AB ). When these three separate sets of features were used to subdivide signature #1, the TCF3-PBX1 patients' cells and cell lines, and related patient samples continued to form a closely related cohort.
Additionally, TCF3-PBX1 patient samples also cluster tightly with the RT features of the pre-B cell sam-ples using signature #1A and with the B-cell lines using signature #1B (Figure 7B) . Importantly, signature #1A includes the gene for the receptor orphan tyrosine kinase receptor 1 (ROR1) (Figure 3B and Supplemental Table S2 ). ROR1 is highly expressed in t(1;19) BCP-ALL blasts and is required for their viability, even though ROR1 is not directly regulated by either the TCF3-PBX1 fusion protein or the pre-B cell receptor (pre-BCR) 38, 39 .
DISCUSSION
Our results demonstrate the potential of RT profiles to identify markers characteristic of BCP-ALL subtypes and to sub-stratify patient samples by outcome. This included the identification of several groups of domains that replicate together uniquely and consistently in TCF3-PBX1 leukemic cells as compared to other BCP-ALL subsets (RT signatures). Evidence that these reflect a retained epigenetic state of the normal cells they resemble is provided by the demonstration of a subset of individual domains (RT features) with correlates in normal CD19+CD34-pre-B cells, but not more primitive normal CD19+CD34+ pro-B cells or more mature B cells. These included ROR1, a gene that is uniquely expressed in the TCF3-PBX1 subtype of BCP-ALL where it is a therapeutic target (Bicocca, 2012) . We also discovered signatures that sub-stratify TCF3-PBX1 patient samples and we identified RT signatures specific to and shared by TCF3-PBX1 as well as NOS BCP-ALL relapse cells. Other subtypes of BCP-ALL cells also contained distinguishing features. We conclude that RT profiles of BCP-ALL cells have stable prevalent clonotypic features operative in normal phenotypes they resemble as well as others with potential prognostic import.
We report several methodologies to analyze RT in normal differentiating hematopoietic cells and leukemic samples from BCP-ALL patients and to normalize them toether for comparative analyses. When possible, the method of choice is E/L Repli-seq 17 , which yields consistently high quality data from small numbers of cells. Samples with low viability can either be be expanded as PDX to regenerate their viability 14 or RT profiles can be generated by a copy number comparison of reads in S-vs. G1-phase cells. Finally, when sufficiently deep WGS is available, RT profiles can be derived from total read copy number 20 . 
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